The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)

Pan, B.
Farrugia, A.
To, L.
Findlay, D.
Green, J.
Lynch, K.
Zannettino, A.

Open link

Publication date

January 2004

DOI

10.1359/jbmr.2004.19.1.147

Publisher

Wiley

Journal

Journal of Bone and Mineral Research

Abstract

© American Society for Bone and Mineral Research.Bisphosphonates are used to prevent osteoclast-mediated bone loss. Zoledronic acid inhibits osteoclast maturation indirectly by increasing OPG protein secretion and decreasing transmembrane RANKL expression in human osteoblasts. The decreased transmembrane RANKL expression seems to be related to the upregulation of the RANKL sheddase, TACE.Beiqing Pan, Amanda N Farrugia, Luen Bik To, David M Findlay, Jonathan Green, Kevin Lynch, Andrew CW Zannettin

Extracted data

We use cookies to provide a better user experience.

Data Protection

The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)

Abstract

Extracted data

The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)

Abstract

Extracted data

Related items

Related items